JAZZ
$181.37
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Intraday
Recent News
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 3.8% return has closely followed the S&P 500.
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
JAZZ vs. ACAD: Which Stock Is the Better Value Option?
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After Recent Share Price Strength
If you are wondering whether Jazz Pharmaceuticals' current share price still offers value, you are not alone. This article will walk through what the numbers say about the stock. The shares most recently closed at US$182.01, with a 10.0% return over the last 30 days, a 31.1% return over 1 year, and a 35.8% return over 3 years, alongside a 4.2% decline over the past week and an 8.6% return over 5 years. Recent news around Jazz Pharmaceuticals has focused on its position in the pharmaceuticals...
Taco Bell Parent, Data Center Play And Two Other Stocks Weather War Storm, Hover Near Highs
Building construction play Argan and three other stocks are notable for scoring new highs amid recent market volatility. Argan touched an all-time high of 469.88 in Wednesday's stock market before pulling back to its 21-day moving average. The building and heavy construction stock has surged as artificial intelligence data centers drive up demand for power plants.